BridgeMD
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events
EU CTIS ID: 2025-520554-11-00
What this study is testing
To evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a])
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participant has provided written informed consent before initiation of any studyspecific activities/procedures.
- Age ≥ 50 years at the time of signing of the Lp(a) screening ICF.
- Lp(a) ≥ 200 nmol/L during Lp(a) screening by a central laboratory using an investigational IVD test. - At least 4 weeks of stable and optimized lipid-lowering therapy consistent with regional/local clinical practice guidelines or according to investigator’s judgment before Lp(a) screening.
- Participants meeting at least one of the following categories (A or B): A. Multiple risk factors for atherosclerotic disease AND/OR B. History of atherosclerosis
You likely can't join if
- Prior acute atherothrombotic qualifying event at any time, defined as prior myocardial infarction, prior stroke, prior transient ischemic attack, or prior acute limb ischemia.
- Prior arterial revascularization at any time suspected to be associated with atherosclerosis.
- History of major bleeding disorder (eg, hemophilia, von Willebrand disease, clotting factor deficiencies, etc).
- Planned arterial revascularization (percutaneous or surgical).
- Fasting triglycerides > 400 mg/dL (4.52 mmol/L) during screening.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Taiwan
- Chile
- Argentina
- Mexico
- Turkey
- Hong Kong
- China
- Brazil
- United Kingdom
- Japan
- Peru
- Canada
- Switzerland
- Korea, Republic of
- Australia
- Colombia
- Malaysia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Taiwan; Chile; Argentina; Mexico; Turkey and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.